SGLT-2 Inhibitors: Mikhail Kosiborod, MD, Highlights the Journey to Pluripotency

Mikhail Kosiborod, MD, a lead investigator for clinical trials of SGLT2 inhibitors, traces the class history from antidiabetic agents to guideline-recommended multidisease treatments.

The April 2021 FDA approval of the sodium glucose co-transporter-2 (SGLT-2) inhibitor dapagliflozin for the treatment of chronic kidney disease (CKD) in adults with CKD and at high risk for disease progression, regardless of diabetes status, was a first for the class of glycosuric agents.

More profoundly for patients with CKD and their health care providers, dapagliflozin is the first agent approved specifically to improve morbidity and mortality associated with the progressive disease.

The steady therapeutic evolution of the SGLT-2 inhibitors has been "a remarkable journey," said Mikhail Kosiborod, MD, in a recent interview with Patient Care Online. Kosiborod is world-renowned for his research in diabetes, cardiovascular disease and cardiometabolic and cardiorenal syndromes. He has been a lead investigator for a number of the studies that have revealed the pluripotent properties of the SGLT2 inhibitor class. He spoke with us about the SGLT-2 inhibitor journey and the historic shift the drugs may promise for patient care and outcomes.

Mikhail N. Kosiborod, MD is Professor of Medicine, University of Missouri Kansas City, Vice President, Research, Saint Luke’s Health System, Executive Director, Cardiometabolic Center Alliance, Director, Cardiometabolic Research and Co-director, Haverty Cardiometabolic Center of Excellence, Saint Luke’s Mid America Heart Institute, Kansas City, MO.